Prestige Biologics

프레스티지바이오로직스 · 334970

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$104.2M (₩143.8B)

Overview

Prestige Biologics provides contract manufacturing and development services for advanced biologic medicines, complex drugs derived from living cells, on behalf of pharmaceutical companies in Korea and abroad.

It sits in the supply chain as a service provider, handling production and development-stage support rather than marketing its own drugs. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates under a model it calls CDEMO (Contract Development, Engineering and Manufacturing Organization), offering clients a flexible manufacturing environment that can be adapted to their specific needs.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$9.1M

▲ +477.8% YoY

Operating profit · FY2025

−US$24.4M

Loss widened

Net income · FY2025

−US$19.9M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$1.3M(₩1.7B)	US$1.6M(₩2.2B)	US$9.1M(₩12.5B)
Operating profit	−US$16M(−₩22.1B)	−US$24.2M(−₩33.4B)	−US$24.4M(−₩33.7B)
Net income	−US$13M(−₩18B)	−US$21.3M(−₩29.4B)	−US$19.9M(−₩27.5B)

Revenue

FY2023US$1.3M
FY2024US$1.6M
FY2025US$9.1M

Operating profit

FY2023−US$16M
FY2024−US$24.2M
FY2025−US$24.4M

Net income

FY2023−US$13M
FY2024−US$21.3M
FY2025−US$19.9M

Key ratios (FY2025)

ROE

-20.3%

Debt/Eq

99.9%

Op. margin

-268.7%

Net margin

-219.2%

Rev. YoY

▲ +477.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?